Abstract
BackgroundThe NIH:OVCAR-3 is a cisplatin refractory cell lineestablished from malignant ascites of a patient with pro-gressive adenocarcinoma of the ovary after combinationchemotherapy with cyclophosphamide, Adriamycin, andcisplatin [1]. Thus, OVCAR3 serves as a model cell linefor drug resistance in ovarian cancer. Here, we perform acomparative transcriptome analysis from the US NationalCancer Institute human tumor cell line anticancer drugscreen (NCI60) dataset [2]. Our results indicate a specificgene transcription profile of OVCAR3 genes relative tonon-cancerous Human Ovarian Surface Epithelial cells(HOSE) and drug sensitive Serous Ovarian CancerEpithelial Samples (CEPI) and SKOV3 cell lines. Pathwayenrichment analysis from OVCAR3 unique transcriptswas conducted using KEGG; Disease and Drug termenrichment used the PharmGKB [3] databases.Materials and methodsDatasets from the NCI60 were obtained from the GeneExpression Omnibus (GEO) of NCBI [4] (OVCAR3 andSKOV3 from series GSE2003, OSE and CEPI from series
Highlights
The NIH:OVCAR-3 is a cisplatin refractory cell line established from malignant ascites of a patient with progressive adenocarcinoma of the ovary after combination chemotherapy with cyclophosphamide, Adriamycin, and cisplatin [1]
Materials and methods Datasets from the NCI60 were obtained from the Gene Expression Omnibus (GEO) of NCBI [4]
Transcriptome analysis of OVCAR3 specific gene expression changes resulted in 160 significant transcripts with a fold change > ±2 and an ANOVA derived Benjamini Hochberg adjusted p-value < 0.001
Summary
The NIH:OVCAR-3 is a cisplatin refractory cell line established from malignant ascites of a patient with progressive adenocarcinoma of the ovary after combination chemotherapy with cyclophosphamide, Adriamycin, and cisplatin [1]. OVCAR3 serves as a model cell line for drug resistance in ovarian cancer. We perform a comparative transcriptome analysis from the US National Cancer Institute human tumor cell line anticancer drug screen (NCI60) dataset [2]. Our results indicate a specific gene transcription profile of OVCAR3 genes relative to non-cancerous Human Ovarian Surface Epithelial cells (HOSE) and drug sensitive Serous Ovarian Cancer Epithelial Samples (CEPI) and SKOV3 cell lines. Pathway enrichment analysis from OVCAR3 unique transcripts was conducted using KEGG; Disease and Drug term enrichment used the PharmGKB [3] databases
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
